Teva announced the launch of Almotriptan Malate Tablets, the generic version of Janssen’s Axert.

Axert is a selective 5-HT1B/1D receptor agonist indicated for the acute treatment of migraine attacks in adults, and acute treatment of migraine headache pain in adolescents aged 12–17 years with a history of migraine attacks lasting ≥4 hours (when untreated). The therapeutic activity of almotriptan in migraine can most likely be attributed to agonist effects at 5-HT1B/1D receptors on the extracerebral, intracranial blood vessels that become dilated during a migraine attack and on nerve terminals in the trigeminal system. Activation of these receptors results in cranial vessel constriction, inhibition of neuropeptide release, and reduced transmission in trigeminal pain pathways.

RELATED: Surgery May Help Adolescents With Frequent Migraines

Almotriptan Malate is available as 6.25mg and 12.5mg strengths in 1×6 and 2×6 blister packs, respectively.

For more information call (888) 838-2872 or visit